Formulation of Fe₃O₄/Acrylate Co-Polymer Nanocomposites as Potential Drug Carriers

Figures & data

FIG. 1 Schematic representation of the preparation of co-polymer coated magnetic nanocomposite particles using the water replacement method.

TABLE 1 Ingredients of co-polymer formulation (weight ratio) and freeze-thaw stability ratio of formulation

	Weight ratio (%)
Formulation code	MeOPEGMA	MMA	BA	QMA	Freeze-thaw stability ratio
F1	15	70	5	0	0.78
F2	15	65	10	10	0.74
F3	15	55	20	10	0.82
F4	15	45	30	10	0.74
F5	15	35	40	10	0.86
F6	15	25	50	10	0.65
F7	5	70	10	15	0.55
F8	5	75	10	10	0.66
F9	5	80	10	5	0.98
F10	5	84	10	1	0.88
F11	5	83.5	10	1.5	0.65

MeOPEGMA = methoxy(polyethylene glycol) methacrylate; MMA = methyl methacrylate (MMA); BA = butyl acrylate; QMA = 2-(methacryloyloxy)ethyl trimethyl ammonium chloride.

FIG. 2 Zeta potential of co-polymer formulations at pH 7.

FIG. 3 Transmission electron microscope images of (a) magnetite and (b) co-polymer-coated magnetic nanocomposite particles.

FIG. 4 X-ray powder diffraction patterns of (a) dried polymer powder, (b) magnetite, and (c) polymer-coated magnetic nanocomposite.

FIG. 5 Zeta potential of (a) co-polymer, (b) magnetite, (c) co-polymer-coated magnetic nanocomposite particles as a function of pH.

FIG. 6 The effect of pH on (a) aspirin adsorption and (b) zeta potential of magnetic nanocomposite particles (initial drug concentration = 800 mg/L at 25°C).

FIG. 7 In vitro release profiles of aspirin from 19, 37, and 53% aspirin-loaded magnetic nanocomposite particles (phosphate buffer solution pH = 7.4, T = 37°C).

FIG. 8 The effect of NaCl concentration on in vitro release profile magnetic nanocomposite particles in deionized water and phosphate buffer solution (pH 7.4, T = 37°C, release time = 24 hr).